Teva Pharmaceutical Industries annual operating income
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Operating Income Growth & History (TEVA)
Teva Pharmaceutical Industries's operating income was $2.16B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.16B | $2.46B | — |
| 2024 | 2024-12-31 | −$303.0M | −$736.0M | — |
| 2023 | 2023-12-31 | $433.0M | $2.63B | — |
| 2022 | 2022-12-31 | −$2.20B | −$3.91B | — |
| 2021 | 2021-12-31 | $1.72B | $5.29B | — |
| 2020 | 2020-12-31 | −$3.57B | −$3.13B | — |
| 2019 | 2019-12-31 | −$443.0M | $1.19B | — |
| 2018 | 2018-12-31 | −$1.64B | $15.85B | — |
| 2017 | 2017-12-31 | −$17.48B | −$19.64B | — |
| 2016 | 2016-12-31 | $2.15B | — | — |
| 2013 | 2013-12-31 | $1.65B | −$556.0M | −25.22% |
| 2012 | 2012-12-31 | $2.21B | −$904.0M | −29.08% |
| 2011 | 2011-12-31 | $3.11B | −$762.0M | −19.68% |
| 2010 | 2010-12-31 | $3.87B | $1.47B | +60.96% |
| 2009 | 2009-12-31 | $2.40B | $1.26B | +110.04% |
| 2008 | 2008-12-31 | $1.15B | −$1.25B | −52.19% |
| 2007 | 2007-12-31 | $2.40B | — | — |
Teva Pharmaceutical Industries quarterly operating income
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$231.0M | −$686.0M | — |
| Q1 2026 | 2026-03-31 | $652.0M | $133.0M | +25.63% |
| Q4 2025 | 2025-12-31 | $301.0M | $330.0M | — |
| Q3 2025 | 2025-09-30 | $882.0M | $933.0M | — |
| Q2 2025 | 2025-06-30 | $455.0M | $460.0M | — |
| Q1 2025 | 2025-03-31 | $519.0M | $737.0M | — |
| Q4 2024 | 2024-12-31 | −$29.0M | −$785.0M | — |
| Q3 2024 | 2024-09-30 | −$51.0M | −$395.0M | — |
| Q2 2024 | 2024-06-30 | −$5.0M | $649.0M | — |
| Q1 2024 | 2024-03-31 | −$218.0M | −$205.0M | — |
| Q4 2023 | 2023-12-31 | $756.0M | $1.70B | — |
| Q3 2023 | 2023-09-30 | $344.0M | −$80.0M | −18.87% |
| Q2 2023 | 2023-06-30 | −$654.0M | $313.0M | — |
| Q1 2023 | 2023-03-31 | −$13.0M | $700.0M | — |
| Q4 2022 | 2022-12-31 | −$940.0M | −$1.02B | — |
| Q3 2022 | 2022-09-30 | $424.0M | −$199.0M | −31.94% |
| Q2 2022 | 2022-06-30 | −$967.0M | −$1.55B | — |
| Q1 2022 | 2022-03-31 | −$713.0M | −$1.15B | — |
| Q4 2021 | 2021-12-31 | $77.0M | −$329.0M | −81.03% |
| Q3 2021 | 2021-09-30 | $623.0M | $4.96B | — |
| Q2 2021 | 2021-06-30 | $582.0M | $409.0M | +236.42% |
| Q1 2021 | 2021-03-31 | $434.0M | $243.0M | +127.23% |
| Q4 2020 | 2020-12-31 | $406.0M | $258.0M | +174.32% |
| Q3 2020 | 2020-09-30 | −$4.34B | −$4.26B | — |
| Q2 2020 | 2020-06-30 | $173.0M | $817.0M | — |
| Q1 2020 | 2020-03-31 | $191.0M | $57.0M | +42.54% |
| Q4 2019 | 2019-12-31 | $148.0M | $3.31B | — |
| Q3 2019 | 2019-09-30 | −$81.0M | −$97.0M | — |
| Q2 2019 | 2019-06-30 | −$644.0M | −$630.0M | — |
| Q1 2019 | 2019-03-31 | $134.0M | −$1.39B | −91.21% |
| Q4 2018 | 2018-12-31 | −$3.16B | $9.85B | — |
| Q3 2018 | 2018-09-30 | $16.0M | −$362.0M | −95.77% |
| Q2 2018 | 2018-06-30 | −$14.0M | $5.73B | — |
| Q1 2018 | 2018-03-31 | $1.52B | $630.0M | +70.39% |
| Q4 2017 | 2017-12-31 | −$13.02B | −$12.88B | — |
| Q3 2017 | 2017-09-30 | $378.0M | −$387.0M | −50.59% |
| Q2 2017 | 2017-06-30 | −$5.74B | −$6.10B | — |
| Q1 2017 | 2017-03-31 | $895.0M | −$270.0M | −23.18% |
| Q4 2016 | 2016-12-31 | −$137.0M | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $765.0M | −$245.0M | −24.26% |
| Q2 2016 · Jun 30 | 2016-06-30 | $361.0M | −$301.0M | −45.47% |
| Q1 2016 · Mar 31 | 2016-03-31 | $1.17B | $416.0M | +55.54% |
| Q3 2016 · Sep 30 | 2015-09-30 | $1.01B | −$102.0M | −9.17% |
| Q2 2016 · Jun 30 | 2015-06-30 | $662.0M | −$263.0M | −28.43% |
| Q1 2016 · Mar 31 | 2015-03-31 | $749.0M | −$223.0M | −22.94% |
| Q3 2014 | 2014-09-30 | $1.11B | $311.0M | +38.83% |
| Q2 2014 | 2014-06-30 | $925.0M | $1.51B | — |
| Q1 2014 | 2014-03-31 | $972.0M | $98.0M | +11.21% |
| Q4 2013 | 2013-12-31 | $560.0M | $230.0M | +69.70% |
| Q3 2013 | 2013-09-30 | $801.0M | $861.0M | — |
| Q2 2013 | 2013-06-30 | −$586.0M | −$1.59B | — |
| Q1 2013 | 2013-03-31 | $874.0M | −$54.0M | −5.82% |
| Q4 2012 | 2012-12-31 | $330.0M | −$280.0M | −45.90% |
| Q3 2012 | 2012-09-30 | −$60.0M | −$1.09B | — |
| Q2 2012 | 2012-06-30 | $1.01B | $410.0M | +68.68% |
| Q1 2012 | 2012-03-31 | $928.0M | $61.0M | +7.04% |
| Q4 2011 | 2011-12-31 | $610.0M | −$164.0M | −21.19% |
| Q3 2011 | 2011-09-30 | $1.03B | −$153.0M | −12.88% |
| Q2 2011 | 2011-06-30 | $597.0M | −$478.0M | −44.47% |
| Q1 2011 | 2011-03-31 | $867.0M | $33.0M | +3.96% |
| Q4 2010 | 2010-12-31 | $774.0M | $362.0M | +87.86% |
| Q3 2010 | 2010-09-30 | $1.19B | $435.0M | +57.77% |
| Q2 2010 | 2010-06-30 | $1.07B | $373.0M | +53.13% |
| Q1 2010 | 2010-03-31 | $834.0M | $296.0M | +55.02% |
| Q4 2009 | 2009-12-31 | $412.0M | $824.0M | — |
| Q3 2009 | 2009-09-30 | $753.0M | $131.0M | +21.06% |
| Q2 2009 | 2009-06-30 | $702.0M | $64.0M | +10.03% |
| Q1 2009 | 2009-03-31 | $538.0M | $241.0M | +81.14% |
| Q4 2008 | 2008-12-31 | −$412.0M | — | — |
| Q3 2008 | 2008-09-30 | $622.0M | — | — |
| Q2 2008 | 2008-06-30 | $638.0M | — | — |
| Q1 2008 | 2008-03-31 | $297.0M | — | — |
Teva Pharmaceutical Industries operating income trends
Over the last five fiscal years, Teva Pharmaceutical Industries's operating income increased from −$3.57B to $2.16B, a change of $5.73B. The latest reported quarter, Q2 2026, shows −$231.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗